ライフサイエンスコーパス: squamous cell carcinoma

1 lls (EpdSCs), which are a cell of origin for squamous cell carcinoma.

2 ectrum of oral epithelial dysplasia and oral squamous cell carcinoma.

3 time after surgery was found for pharyngeal squamous cell carcinoma.

4 ux surgery prevents laryngeal and pharyngeal squamous cell carcinoma.

5 ncrease the risk of laryngeal and pharyngeal squamous cell carcinoma.

6 in patients with locally advanced cutaneous squamous cell carcinoma.

7 tivity in patients with metastatic cutaneous squamous cell carcinoma.

8 associated with esophageal adenocarcinoma or squamous cell carcinoma.

9 have sex with men (MSM) are at risk of anal squamous cell carcinoma.

10 cerous lesion that can progress to cutaneous squamous cell carcinoma.

11 and also the leading cause of mortality - is squamous cell carcinoma.

12 rstanding of carcinogenesis in head and neck squamous cell carcinoma.

13 or for nonmelanoma skin cancer, particularly squamous cell carcinoma.

14 cells and evident in patients with basal or squamous cell carcinoma.

15 ival PL with and without progression to oral squamous cell carcinoma.

16 ant anti-cancer therapy in human oral cavity squamous cell carcinoma.

17 uman papillomavirus-associated oropharyngeal squamous cell carcinoma.

18 ll carcinoma and possibly also of pharyngeal squamous cell carcinoma.

19 Biopsy revealed poorly differentiated, squamous cell carcinoma.

20 d efficacy in the treatment of head and neck squamous cell carcinoma.

21 1 is highly expressed in CSCs of oral cavity squamous cell carcinoma.

22 e therapy for the treatment of head-and-neck squamous cell carcinoma.

23 , contribute to the development of cutaneous squamous cell carcinoma.

24 s with recurrent or metastatic head-and-neck squamous cell carcinoma.

25 S) lesions are the pre-invasive precursor to squamous cell carcinoma.

26 t are highly selected, driving head and neck squamous cell carcinoma.

27 th men (MSM) are at risk for developing anal squamous cell carcinoma.

28 neck in patients with primary head and neck squamous cell carcinoma.

29 with previously treated advanced oesophageal squamous cell carcinoma.

30 t to CHCT/MRI in patients with head and neck squamous cell carcinoma.

31 ll cell carcinoma, urothelial carcinoma, and squamous cell carcinoma.

32 and metastasis of mouse and human cutaneous squamous cell carcinoma.

33 noma from tobacco and alcohol use-associated squamous cell carcinoma.

34 d highly aggressive form of undifferentiated squamous cell carcinoma.

35 rspective in a mouse model of salivary gland squamous cell carcinoma.

36 on appearance and risk factors in predicting squamous cell carcinoma.

37 umor microenvironment (TME) of head and neck squamous cell carcinoma.

38 se phenformin for the treatment of cutaneous squamous cell carcinomas.

39 past history of numerous cutaneous basal and squamous cell carcinomas.

40 TET1 is overexpressed in adenocarcinoma and squamous cell carcinomas.

41 iple human cancers, including in 39% of lung squamous cell carcinomas.

42 with cryotherapy: 5 conjunctival melanoma, 4 squamous cell carcinoma, 1 sebaceous carcinoma, and 1 at

43 y), sebaceous gland carcinoma (35 patients), squamous cell carcinoma (26 patients), Merkel cell carci

44 etil) and following a diagnosis of cutaneous squamous cell carcinoma (4.21, 2.69-0.94).

45 The majority of patients had squamous cell carcinoma (87.8%).

46 usted OR = 0.86; 95% CI: 0.80-0.92), but not squamous cell carcinoma (adjusted OR = 0.99; 95% CI: 0.9

47 ma, esophageal adenocarcinoma, or esophageal squamous cell carcinoma.Among older American adults, bot

48 possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma.

49 gically confirmed locally advanced cutaneous squamous cell carcinoma and an Eastern Cooperative Oncol

50 is contemporary cohort include prior CLL for squamous cell carcinoma and basal cell carcinoma and red

51 er lead to specific immunophenotypes in lung squamous cell carcinoma and could potentially serve as b

52 SVC112 reduces tumor growth in head and neck squamous cell carcinoma and increases the effects of rad

53 single-agent treatment in both head and neck squamous cell carcinoma and non-small cell lung cancer.

54 x surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal

55 are transcriptionally regulated by SPIN1 in squamous cell carcinoma and suggest that SPIN1 may have

56 nsive loss of heterozygosity, including lung squamous cell carcinoma and triple-negative breast cance

57 ses (including 11,273 adenocarcinomas, 7,426 squamous cell carcinoma, and 2,664 small-cell carcinoma

58 g this pipeline to lung adenocarcinoma, lung squamous cell carcinoma, and glioblastoma, genes highly

59 y treated patients with advanced oesophageal squamous cell carcinoma, and might represent a new stand

60 ith increasing risks of lung adenocarcinoma, squamous cell carcinoma, and small cell carcinoma.

61 ical (PEC) immunosensor by immobilizing anti-squamous cell carcinoma antigen (anti-SCCA).

62 ell lung cancer (NSCLC) cells, we identified squamous cell carcinoma antigen recognized by T-cells 3

63 Keratinocyte carcinomas, including basal and squamous cell carcinomas, are the most common human canc

64 In SKH1-E mice prone to squamous cell carcinoma, ASA reduced plasma and skin pro

65 e-matched tumors from patients with basal or squamous cell carcinoma before and after anti-PD-1 thera

66 in certain types of cancer cells, including squamous cell carcinoma, brain tumor, and osteosarcoma,

67 ignant lesions (PMLs) are precursors of lung squamous cell carcinoma, but have variable outcome, and

68 In addition, knockout of ZDHHC19 in lung squamous cell carcinoma cells significantly blocks STAT3

69 uman papillomavirus-associated oropharyngeal squamous cell carcinoma could maintain historical rates

70 Our previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identi

71 elanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by solar ultrav

72 Nonmelanoma skin cancer such as cutaneous squamous cell carcinoma (cSCC) is the most common form o

73 invasion (PNI) and desmoplasia on cutaneous squamous cell carcinoma (CSCC) recurrence and metastasis

74 RNA screen to identify targets for cutaneous squamous cell carcinoma (cSCC) therapy in the ubiquitin/

75 ar composition and architecture of cutaneous squamous cell carcinoma (cSCC), we combined single-cell

76 ansplant recipient with metastatic cutaneous squamous cell carcinoma (CSCC).

77 recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 7

78 papillomaviruses (beta-HPVs) cause cutaneous squamous cell carcinomas (cSCCs) in a subset of immunoco

79 as co-factor in the development of cutaneous squamous cell carcinomas (cSCCs), particularly in immuno

80 Cutaneous squamous cell carcinoma (cuSCC) is the second most commo

81 y to ultraviolet radiation-induced cutaneous squamous cell carcinoma (cuSCC).

82 Female patients had higher incidence of squamous cell carcinoma despite lower prevalence of beha

83 from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion

84 ultiple myeloma, oral cancer, and esophageal squamous cell carcinoma did not survive correction for m

85 ing head and neck, cervical and oesophageal, squamous cell carcinomas display loss of ZNF185 expressi

86 Equine penile squamous cell carcinoma (EpSCC) is a relatively common c

87 n a detailed immune cell atlas of esophageal squamous cell carcinoma (ESCC) at single-cell resolution

88 hy as a potential risk factor for esophageal squamous cell carcinoma (ESCC) have been inconsistent.

89 r, drug sensitivity biomarkers in esophageal squamous cell carcinoma (ESCC) have not been widely expl

90 Esophageal squamous cell carcinoma (ESCC) is among the most aggress

91 l dependency in SMARCA2-deficient esophageal squamous cell carcinoma (ESCC) models, reciprocal to the

92 Esophageal squamous cell carcinoma (ESCC) ranks fourth among cancer

93 nd regulatory mechanism of YAP in esophageal squamous cell carcinoma (ESCC) remains unclear.

94 Detection of patients with esophageal squamous cell carcinoma (ESCC) who do not benefit from s

95 of the highest reported rates of esophageal squamous cell carcinoma (ESCC) worldwide.

96 A-31 (miR-31) is overexpressed in esophageal squamous cell carcinoma (ESCC), a deadly disease associa

97 axis occurs at high frequency in esophageal squamous cell carcinoma (ESCC), where it promotes ESCC d

98 the etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC).

99 acterize the oncogenic drivers of esophageal squamous cell carcinoma (ESCC).

100 is linked to an increased risk of esophageal squamous cell carcinoma (ESCC).

101 is approach to a sample of 525 head and neck squamous cell carcinoma exomes, producing a rank-ordered

102 In a mouse model of hypopharyngeal squamous cell carcinoma (FaDu), APT MRI showed that a re

103 in patients with locally advanced cutaneous squamous cell carcinoma for whom there was no widely acc

104 prostate, pancreas, lung adenocarcinoma, and squamous cell carcinoma) for the frequency of codon muta

105 te staging of viral-associated oropharyngeal squamous cell carcinoma from tobacco and alcohol use-ass

106 ocally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and a

107 In lung adenocarcinoma, but not lung squamous cell carcinoma, geometrical irregularity and co

108 d alpha-ketoglutarate production antagonizes squamous cell carcinoma growth.

109 -like protease/differentially expressed in a squamous cell carcinoma (HAT/DESC) cluster of membrane-a

110 papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival when treated

111 Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with convent

112 d that cortex genes subdivided Head and Neck Squamous Cell Carcinoma (HNSC) tumors and Pheochromocyto

113 andscape in the development of head and neck squamous cell carcinomas HNSCC from potentially premalig

114 h newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinica

115 cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that pred

116 Head and neck squamous cell carcinoma (HNSCC) arises through exposure

117 Head and neck squamous cell carcinoma (HNSCC) associated with high-ris

118 n of metastatic lymph nodes in head and neck squamous cell carcinoma (HNSCC) cases.

119 an lung cancer cells and human head and neck squamous cell carcinoma (HNSCC) cell lines (UM-SCC-47 an

120 Interrogation of head and neck squamous cell carcinoma (HNSCC) cell lines and patient t

121 Although head and neck squamous cell carcinoma (HNSCC) has in the past been lar

122 Head and neck squamous cell carcinoma (HNSCC) is a common and debilita

123 Head and neck squamous cell carcinoma (HNSCC) is a disease of signific

124 papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) is biologically distinct

125 Head and neck squamous cell carcinoma (HNSCC) is characterized by the

126 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common

127 Tumor hypoxia in head-and-neck squamous cell carcinoma (HNSCC) leads to an immunosuppre

128 Malignant features of head and neck squamous cell carcinoma (HNSCC) may be derived from the

129 control group in an orthotopic head and neck squamous cell carcinoma (HNSCC) model.

130 have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its ove

131 Head and neck squamous cell carcinoma (HNSCC) presents a major public

132 Cells from head and neck squamous cell carcinoma (HNSCC) primary tumors had signi

133 val in patients with recurrent head and neck squamous cell carcinoma (HNSCC) than chest x-ray (CXR) p

134 3), a metastatic biomarker for head and neck squamous cell carcinoma (HNSCC), along with two accompan

135 type of head and neck cancer, head and neck squamous cell carcinoma (HNSCC), can develop therapeutic

136 In head and neck squamous cell carcinoma (HNSCC), cell migration facilita

137 roved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the managem

138 t the two most common sites of head and neck squamous cell carcinoma (HNSCC), the lateral border of t

139 Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell de

140 containing 4 (ZSCAN4) in human head and neck squamous cell carcinoma (HNSCC).

141 resistance, and recurrence in head and neck squamous cell carcinoma (HNSCC).

142 s with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC).

143 and are known collectively as head and neck squamous cell carcinoma (HNSCC).

144 (chemo)radiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC).

145 t commonly altered oncogene in head and neck squamous cell carcinoma (HNSCC).

146 ab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC).

147 promises for the treatment of head and neck squamous cell carcinoma (HNSCC).

148 ipheral blood in patients with head and neck squamous cell carcinoma (HNSCC).

149 benefit in most patients with head and neck squamous cell carcinoma (HNSCC).

150 cological decision support for Head and Neck Squamous Cell Carcinoma (HNSCC).

151 thway plays a critical role in head and neck squamous cell carcinoma (HNSCC).

152 nt escalation in patients with head and neck squamous cell carcinoma (HNSCC).

153 nhibits the activity of CBI in head and neck squamous cell carcinoma (HNSCC).

154 lified and overexpressed in head and neck of squamous cell carcinoma (HNSCC).

155 as a first-line treatment for head and neck squamous cell carcinoma (HNSCC).

156 of immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC).

157 s with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according t

158 une microenvironment (TIME) of head and neck squamous cell carcinomas (HNSCC) and other solid maligna

159 n, with disparate incidence of head and neck squamous cell carcinomas (HNSCC), including oral cavity

160 me high FGF19 amplification in head and neck squamous cell carcinomas (HNSCC), which is associated wi

161 treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure

162 mal 1 (FXR1) is upregulated in head and neck squamous cell carcinomas (HNSCCs) and expressed as at le

163 nging therapeutic landscape of head and neck squamous cell carcinomas (HNSCCs) that can arise in the

164 anisms remain undefined in the head and neck squamous cell carcinomas (HNSCCs).

165 Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16(INK4

166 o human papillomavirus-related oropharyngeal squamous cell carcinoma (HPV + OPSCC).

167 s on the incidence of cases of invasive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, w

168 s on the incidence of cases of invasive-anal-squamous-cell-carcinoma (IASCC) in HIV-1-infected subjec

169 lopment of UV irradiation-mediated cutaneous squamous cell carcinoma in mice.

170 ential therapeutic targets for prevention of squamous cell carcinoma in patients with Kindler syndrom

171 Squamous cell carcinoma in situ (SCCIS) is a prevalent p

172 successfully established a PDX model of lung squamous cell carcinoma in which the grafts recapitulate

173 coexpressing IL23 in the stroma of cervical squamous cell carcinomas in situ.

174 and potentiates the progression of invasive squamous cell carcinomas in vivo.

175 onary infection, as well as autoimmunity and squamous cell carcinoma, in addition to even more broad

176 fferentiation and is frequently disrupted in squamous cell carcinomas, in which Notch is tumor suppre

177 The incidences of squamous cell carcinomas (incidence rate ratio = 9.8; 95

178 cell carcinomas form 'buds', while invasive squamous cell carcinomas initiate as 'folds'.

179 esponsive skin cancers, invasive and in situ squamous cell carcinoma, Kaposi sarcoma, and Merkel cell

180 n and risk of oesophageal adenocarcinoma and squamous cell carcinoma, liver and endometrial cancer we

181 Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC)

182 Mechanisms of lung squamous cell carcinoma (LSCC) development are poorly un

183 Laryngeal squamous cell carcinoma (LSCC) responds to 17beta-estrad

184 lidated in a secondary unrelated set of lung squamous cell carcinoma (LUSC) and was shown to be drive

185 tome data of lung adenocarcinomas (LUAD) and squamous cell carcinomas (LUSC) from The Cancer Genome A

186 eal adenocarcinoma (EA; n = 855), esophageal squamous cell carcinoma (n = 267), and gastric cancer (c

187 the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n = 39) were decreased after an

188 Invasive squamous cell carcinoma (n = 51, 41%) was the most commo

189 tumor proportion score [TPS] >= 50%) and non-squamous cell carcinoma (non-SCC), the Expert Panel reco

190 pression data from patients with oral cavity squamous cell carcinoma (OCSCC) in order to map metabolo

191 have recurrent copy-number variants in three squamous-cell carcinomas (oesophageal, head and neck and

192 WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the ge

193 ronic urogenital schistosomiasis can lead to squamous cell carcinoma of the bladder.

194 f Gynecology and Obstetrics (FIGO) stage IB3 squamous cell carcinoma of the cervix.

195 atients with biopsy-proven adenocarcinoma or squamous cell carcinoma of the esophagus with an initial

196 al cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), me

197 To identify genetic variants for risk of squamous cell carcinoma of the head and neck (SCCHN), we

198 ased chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

199 endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-smal

200 fe for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data

201 the management of the neck in patients with squamous cell carcinoma of the oral cavity and oropharyn

202 nts with platinum-resistant or early-failure squamous cell carcinoma of the oral cavity were eligible

203 For radical resection of squamous cell carcinoma of the oral cavity, a tumor-free

204 Remarkably high risks for second in situ squamous cell carcinoma of the skin were found after Kap

205 Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 r

206 In particular, the risk of squamous cell carcinoma of the skin-which has been assoc

207 ere identified for each invasive and in situ squamous cell carcinoma of the skin.

208 the HER2 signaling axis to drive aggressive squamous cell carcinomas of the head and neck (HNSCC) an

209 Squamous cell carcinomas of the head and neck (HNSCC) ar

210 trated clinical efficacy in the treatment of squamous cell carcinomas of the head and neck.

211 erapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival p

212 ndices of UVB-induced DNA damage and delayed squamous cell carcinoma onset induced by chronic UVB.

213 The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rapidly increas

214 Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing

215 ortant determinant of oral and oropharyngeal squamous cell carcinoma (OPSCC) outcomes, yet most of th

216 deline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to b

217 trace elemental composition of oropharyngeal squamous cell carcinoma (OPSCC), we performed elemental

218 apillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

219 r human papillomavirus- driven oropharyngeal squamous cell carcinomas (OpSCC) represent distinct clin

220 HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC) we noticed that, while

221 ffer from other solid tumors like esophageal squamous-cell carcinoma or glioma.

222 space invasion, IA2, or IB1 adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of t

223 New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed.

224 voke cancer pain.SIGNIFICANCE STATEMENT Oral squamous cell carcinoma (OSCC) is one of the most painfu

225 Oral squamous cell carcinoma (OSCC) is one of the most painfu

226 Oral squamous cell carcinoma (OSCC) is the most common head a

227 Oral squamous cell carcinoma (OSCC) is the most common malign

228 Oral squamous cell carcinoma (OSCC) is the most common type o

229 coagulable state among individuals with oral squamous cell carcinoma (OSCC) is uncertain.

230 ess this gap, we used a murine model of oral squamous cell carcinoma (OSCC) of the tongue to investig

231 Patients with oral squamous cell carcinoma (OSCC) present significant alter

232 Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is the eighth-most commo

233 esis mirrors the heterogeneity of human oral squamous cell carcinoma (OSCC), we have performed genomi

234 egional lymph node metastasis (RLNM) in oral squamous cell carcinoma (OSCC).

235 results and revolutionizes treatment of oral squamous cell carcinoma (OSCC).

236 by genetic alterations in patients with oral squamous cell carcinoma (OSCC).

237 apillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OSCC).

238 y but insufficient cause of a subset of oral squamous cell carcinomas (OSCCs) that is increasing mark

239 hageal cancers and were more associated with squamous cell carcinomas (P = 0.04).

240 In human actinic keratosis, a precursor of squamous cell carcinoma, p16(INK4a)-expressing cells are

241 Lung adenocarcinoma and lung squamous cell carcinoma patients had the lowest survival

242 al rates of lung, cervical and head and neck squamous cell carcinoma patients.

243 For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy

244 Penile squamous cell carcinoma (PSCC) accounts for over 95% of

245 The incidence of penile squamous cell carcinoma (PSCC) has increased in develope

246 resectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1 expression)

247 Squamous cell carcinoma-related oncogene (SCCRO)/DCUN1D1

248 dence rates, prognosis of invasive cutaneous squamous cell carcinoma remains poor, mainly due to lack

249 es demonstrate that reduced FEV(1) increases squamous cell carcinoma risk (odds ratio (OR) = 1.51, 95

250 Here, we analyzed a dataset of lung squamous cell carcinoma samples from The Cancer Genome A

251 mor xenograft/allograft (human head and neck squamous cell carcinoma SAS/mouse breast carcinoma 4T1)

252 f transcription factors, is overexpressed in squamous cell carcinoma (SCC) and associated with poor p

253 -value thresholds were chosen from published squamous cell carcinoma (SCC) and basal cell carcinoma (

254 Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are both derived from epid

255 is (AK), Intraepidermal Carcinoma (IEC), and Squamous Cell Carcinoma (SCC) are generally considered t

256 Murine squamous cell carcinoma (SCC) can be initiated by hair f

257 Basal tumor propagating cells (TPCs) control squamous cell carcinoma (SCC) growth by self-renewing an

258 Epidermal squamous cell carcinoma (SCC) is a common and highly inv

259 Squamous cell carcinoma (SCC) is a global public health

260 Cutaneous squamous cell carcinoma (SCC) is one of the most common

261 ctrum of diseases from dysplasia to invasive squamous cell carcinoma (SCC) of the conjunctiva.

262 prone actinic keratoses (AKs) and aggressive squamous cell carcinoma (SCC) subtypes.

263 problem, we designed a skin cancer model for squamous cell carcinoma (SCC) that can be effectively ch

264 tematic review describing the burden of anal squamous cell carcinoma (SCC), and its surrogates, in SO

265 f medical comorbidities, lower proportion of squamous cell carcinoma (SCC), and more positive lymph n

266 cal benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though the stroma is

267 agement for head and neck cancers, including squamous cell carcinoma (SCC), involves surgical resecti

268 romosome end fusions that also occur in skin Squamous Cell Carcinoma (SCC)-associated CAFs, in which

269 tures of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

270 l cell carcinoma (BCC) or invasive cutaneous squamous cell carcinoma (SCC).

271 is development and a key oncogenic driver in squamous cell carcinomas (SCC).

272 Squamous cell carcinomas (SCCs) account for the majority

273 Skin squamous cell carcinomas (SCCs) are a major cause of dea

274 Squamous cell carcinomas (SCCs) arising from aerodigesti

275 We report that CAFs from skin squamous cell carcinomas (SCCs) display chromosomal alte

276 Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growt

277 Examination of human papillomas and squamous cell carcinomas (SCCs) revealed that TC-PTP exp

278 Two histologic subtypes of squamous cell carcinomas (SCCs) were identified-SCCs wit

279 ut of 147 primary cervical cancers, 113 were squamous cell carcinomas (SCCs), and 34 were adenocarcin

280 Oral cancers, primarily squamous cell carcinomas (SCCs), progress either slowly

281 -3.86), for basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), respectively.

282 melanomas, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs).

283 Subjects with basal or squamous cell carcinoma, scheduled for Mohs surgery, wer

284 ded patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-year

285 in adenocarcinoma (ADC, 72.5%) compared with squamous cell carcinoma (SQCC, 54.4%).

286 uman papillomavirus-associated oropharyngeal squamous-cell carcinoma stabilized, and quality of life

287 s with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation o

288 Vmax and EUS for nodal disease was higher in squamous cell carcinoma than adenocarcinoma.

289 ter chemopreventive efficacy for UVB-induced squamous cell carcinoma than melanoma mouse models.

290 Patients with head-and-neck squamous cell carcinoma that progressed during or after

291 We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role i

292 rend to higher overall complication rates in squamous cell carcinoma versus adenocarcinoma (65% vs 51

293 d adenocarcinoma (83%); however, the rate of squamous cell carcinoma was significantly higher in fema

294 The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10

295 of ocular surface or ocular adnexal invasive squamous cell carcinomas were identified in pathology ca

296 In multivariable models, risk factors for squamous cell carcinomas were increased age (P < 0.0001)

297 phological stages of the development of lung squamous cell carcinoma, which includes 122 well-annotat

298 Patients with head and neck squamous cell carcinoma who underwent surgical resection

299 35), and a significant difference in ARDS in squamous cell carcinoma with 14% versus 2% in adenocarci

300 BCCs usually maintain HH pathway activation, squamous cell carcinomas with Ras/MAPK pathway activatio